06.05.2009: Rostock/San Francisco NeuroProof® GmbH of Rostock/Germany (www.neuroproof.com) presented its screening technology, which is used for preclinical development of neuroactive drugs and safety pharmacology, to select California biotech companies in a recent US visit.
This trip to explore possible collaborations between Neuroproof and California biotech companies was organized by Brinkhaus Life Science Consulting (www.biotech-alliances.com). Dr. Olaf Schroeder, Managing Director of NeuroProof® GmbH, commented: “Working with Brinkhaus Life Science Consulting allowed us to present our screening technology to California biotech companies. We are glad we took advantage of this opportunity. We had some promising discussions and we are looking forward to possible deals.
Brinkhaus Life Science Consulting (www.biotech-alliances.com) facilitates strategic alliances and collaboration deals between life science companies. They provided the collaboration concept for NeuroProof GmbH and set up the meetings. Brinkhaus Life Science Consulting has offices in the Bay Area and in Germany. Dr. Frank Brinkhaus, Director of Brinkhaus Life Science Consulting notes that: “NeuroProof® GmbH is a young biotech company with a unique screening technology that has the potential to shorten development time considerably and thereby cut costs on a substantial scale. We were excited to b able to introduce NeuroProof® GmbH’s breakthrough technology to select California biotech companies”.
Brinkhaus Life Science Consulting (www.biotech-alliances.com) supports life science companies in their efforts to expand and globalize their business development and research activities. Dr. Frank Brinkhaus explains: “Scientific and commercial breakthrough is almost always the result of collaboration or of strategic partnering. We provide clearly defined collaboration concepts and then help our clients find, structure and implement collaboration deals that support their goals, including in-licensing and out-licensing arrangements. We manage all phases of the process from concept through deal execution.
Successful strategic alliances and collaborations are critical elements in the overall business strategy of today’s life science companies. In fact, biotechnology companies are increasingly looking for collaboration partners with specific core capabilities and resources that can help them to develop and to commercialize their products. In the current economic climate, where new sources of funding are difficult to come by, many biotech companies need to come up with more creative ways of financing their operations. Forming an advantageous strategic alliance with a suitable industry partner or setting up a gainful collaboration can be a viable option.
NeuroProof® GmbH offers screening services that analyze and clarify the complex effects of substances on the functions of the brain and on the whole central nervous system. The effect of potential medications on the central nervous system and possible neuro-toxic effects can be predicted early by means of these results. This makes it possible to considerably accelerate the pre-clinical development of CNS drugs and to reduce costs. Only a few companies in the world are able to cultivate primary neuron/glia-cocultures on MEA-neuro-chips. With this technology the specific nervous tissue taken from fetal mice can be kept alive for days and weeks. MEA-neuro-chips record the electronic patterns of action potentials of single neurons in the complex network, which can then be interpreted afterwards. The effect of CNS drugs can thus be examined directly. This was not previously possible.
